Related Experiment Videos
Summary
Diltiazem did not prevent vasospasm after subarachnoid hemorrhage in this trial. While it slightly increased bleeding time, no adverse clinical effects or changes in rebleeding rates were observed, suggesting further study is not warranted.
Area of Science:
- Neurology
- Pharmacology
- Critical Care Medicine
Background:
- Subarachnoid hemorrhage frequently causes cerebral vasospasm.
- Calcium antagonists are explored for vasospasm prevention.
- Diltiazem is a calcium antagonist under investigation.
Purpose of the Study:
- To evaluate the efficacy of diltiazem in preventing vasospasm post-subarachnoid hemorrhage.
- To assess the safety and clinical effects of diltiazem in this patient population.
Main Methods:
- Phase I and II clinical trial design.
- Administration of diltiazem to patients with subarachnoid hemorrhage.
- Monitoring for vasospasm, bleeding time, clinical effects, and rebleeding rates.
Main Results:
- Diltiazem showed no documented effect on preventing vasospasm.
- A trend towards increased bleeding time was observed.
- No detrimental clinical outcomes or changes in rebleeding rates were noted.
Conclusions:
- Diltiazem is ineffective for preventing vasospasm in subarachnoid hemorrhage.
- Further randomized trials of diltiazem for this indication are not recommended due to cost and time inefficiency.